2.3 Refractory ARDS: Prone Positioning, Neuromuscular Blockade & VV-ECMO

ABIM Critical Care Medicine Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Orientation: Format, Blueprint & Study Strategy

1.1 ABIM Critical Care Medicine Exam: Format, Blueprint & Study Strategy

2 Chapter 2: Acute Respiratory Failure & ARDS

2.1 ARDS Definition, Pathophysiology & Phenotypes 2.2 Lung-Protective Mechanical Ventilation 2.3 Refractory ARDS: Prone Positioning, Neuromuscular Blockade & VV-ECMO

3 Chapter 3: Obstructive Airways, Pulmonary Vascular & Pleural Emergencies

3.1 Severe Asthma & COPD Exacerbations in the ICU 3.2 Massive & Submassive Pulmonary Embolism 3.3 Pulmonary Hypertension & Right Ventricular Failure in the ICU 3.4 Massive Hemoptysis, Complex Pleural Effusions & Thoracic Drainage

4 Chapter 4: Airway, Parenchymal & Nonthrombotic Pulmonary Emergencies

4.1 Airway Management, Upper-Airway Obstruction & Artificial-Airway Complications 4.2 Diffuse Alveolar Hemorrhage, Interstitial Lung Disease, Pulmonary Vasculitis & Noncardiogenic Edema 4.3 Severe Community-Acquired & Viral Pneumonia 4.4 Nonthrombotic Embolism (Air, Fat, Amniotic Fluid, Tumor, Septic) & Acute Chest Syndrome

5 Chapter 5: Mechanical Ventilation Modes, Dyssynchrony & Liberation

5.1 Mechanical Ventilator Modes & Advanced Breath Delivery 5.2 Patient-Ventilator Dyssynchrony & Waveform Analysis 5.3 Ventilator Liberation, Spontaneous Breathing Trials & Post-Extubation Support

6 Chapter 6: Shock Syndromes & Hemodynamic Principles

6.1 Shock Classification, Cellular Pathophysiology & Biomarkers 6.2 Hemodynamic Monitoring: Arterial Lines, CVP & Pulmonary Artery Catheter 6.3 Dynamic Assessment of Fluid Responsiveness & Resuscitation Targets

7 Chapter 7: Vasoactive Therapies & Mechanical Circulatory Support

7.1 Vasopressors & Inotropes: Pharmacology & Clinical Titration 7.2 Temporary Mechanical Circulatory Support: IABP, Impella & TandemHeart 7.3 Venoarterial ECMO (VA-ECMO) & Differential Hypoxemia 7.4 Post-Cardiac Arrest Care, Targeted Temperature Management & Neuroprognostication

8 Chapter 8: Acute Kidney Injury & Renal Replacement Therapy

8.1 KDIGO AKI Classification, Etiologies & Diagnostic Evaluation 8.2 Continuous Renal Replacement Therapy (CRRT) vs Intermittent Hemodialysis 8.3 Indications & Timing for RRT in Critical Illness: AKIKI & STARRT-AKI

9 Chapter 9: Electrolyte, Acid-Base & Endocrine Emergencies

9.1 Severe Dysnatremias: Hyponatremia, Hypernatremia & Osmotic Demyelination 9.2 Potassium, Calcium, Magnesium & Phosphate Disorders 9.3 Complex & Mixed Acid-Base Disorders: Boston vs Copenhagen vs Stewart 9.4 Endocrine Crises: DKA, HHS, Thyroid Storm, Myxedema Coma & Adrenal Crisis

10 Chapter 10: Glycemic Control, Hyperammonemia, Pituitary & Adrenal Disorders

10.1 ICU Glycemic Control & Severe Hypoglycemia 10.2 Non-Hepatic Hyperammonemia & Metabolic Encephalopathy 10.3 Pituitary Emergencies, Adrenal Excess & Critical Illness-Related Corticosteroid Insufficiency

11 Chapter 11: Acute Coronary Syndromes & Cardiac Arrhythmias

11.1 Acute Coronary Syndromes & Mechanical Complications of Myocardial Infarction 11.2 Critical Tachyarrhythmias: Atrial Fibrillation with RVR, VT & VF 11.3 Critical Bradyarrhythmias, Conduction Blocks & Temporary Cardiac Pacing

12 Chapter 12: Acute Heart Failure, Valvular & Pericardial Emergencies

12.1 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 12.2 Acute Valvular Regurgitation & Prosthetic Valve Emergencies 12.3 Pericardial Tamponade & Acute Aortic Syndromes

13 Chapter 13: Myocardial Disease, Hypertensive & Cardiac Device Emergencies

13.1 Fulminant Myocarditis, Stress & Peripartum Cardiomyopathy, and Hypertrophic Cardiomyopathy 13.2 Hypertensive Emergencies & Ruptured Abdominal Aortic Aneurysm 13.3 Implanted Cardiac Devices, LVAD Emergencies & Electrical Storm

14 Chapter 14: Sepsis & Systemic Infectious Diseases

14.1 Sepsis-3 Definitions & Surviving Sepsis Campaign 2026 Guidelines 14.2 Refractory Septic Shock & Adjunctive Therapies 14.3 Multidrug-Resistant Pathogens & Antimicrobial Stewardship in the ICU

15 Chapter 15: ICU-Acquired & Severe Focal Infections

15.1 Hospital-Acquired & Ventilator-Associated Pneumonia 15.2 Central Line-Associated Bloodstream Infections & Catheter-Associated UTIs 15.3 Intra-Abdominal Sepsis, Necrotizing Soft Tissue Infections & CNS Infections

16 Chapter 16: Focal, Special-Host & Systemic Infections

16.1 CNS Infections Beyond Bacterial Meningitis: Encephalitis, Brain Abscess & Epidural Abscess 16.2 Infections in the Immunocompromised Host, Tropical & Bioterror Infections 16.3 Infective Endocarditis, Device Infections & Other Focal Cardiovascular Infections 16.4 Antimicrobial Pharmacokinetics, Allergy, Toxicity & Infection Prevention 16.5 Gastrointestinal & Hepatobiliary Infections: Fulminant C. difficile, Typhlitis, CMV Colitis & Abscesses

17 Chapter 17: Neurocritical Care & Coma

17.1 Coma, Altered Mental Status & Acute Delirium in the ICU 17.2 Status Epilepticus & Non-Convulsive Status Epilepticus 17.3 Acute Ischemic Stroke & Intracranial Hemorrhage

18 Chapter 18: Cerebrovascular Syndromes, Encephalopathy & Withdrawal States

18.1 Cerebral Venous Sinus Thrombosis, PRES & Reversible Cerebral Vasoconstriction Syndrome 18.2 Alcohol & Sedative Withdrawal, Wernicke Encephalopathy & Drug-Induced Encephalopathy

19 Chapter 19: Intracranial Hypertension & Neuromuscular Weakness

19.1 Intracranial Pressure Monitoring, Cerebral Perfusion & Tiered ICP Management 19.2 Acute Neuromuscular Respiratory Failure, ICU-Acquired Weakness & Brain Death Determination

20 Chapter 20: Traumatic Brain Injury, Spinal Cord Injury & Toxin-Mediated Paralysis

20.1 Traumatic Brain Injury Management & Paroxysmal Sympathetic Hyperactivity 20.2 Acute Spinal Cord Injury, Neurogenic Shock & Autonomic Dysreflexia 20.3 Toxin-Mediated Paralysis & Neuromuscular Crises: Botulism, Tetanus, Tick Paralysis & Myasthenic Crisis

21 Chapter 21: Gastrointestinal, Hepatic & Abdominal Emergencies

21.1 Acute Upper & Lower Gastrointestinal Bleeding in the ICU 21.2 Acute Liver Failure & Severe Acute Pancreatitis 21.3 Abdominal Compartment Syndrome & Acute Mesenteric Ischemia

22 Chapter 22: Luminal GI Emergencies & Complications of Cirrhosis

22.1 Esophageal, Gastric & Bowel Emergencies: Perforation, Obstruction, Ogilvie Syndrome & Colonic Ischemia 22.2 Complications of Cirrhosis: Alcohol-Associated Hepatitis, Hepatorenal Syndrome & Pulmonary Vascular Syndromes

23 Chapter 23: Trauma, Burns & Perioperative Critical Care

23.1 Polytrauma Resuscitation, Damage Control & Massive Transfusion 23.2 Severe Burn Injury, Inhalation Injury & Environmental Emergencies 23.3 Perioperative Critical Care for High-Risk Surgical Patients

24 Chapter 24: Thoracic Trauma, Environmental Injury & Obstetric Critical Care

24.1 Thoracic Trauma: Flail Chest, Pulmonary Contusion, Great Vessel & Tracheobronchial Injury 24.2 Environmental Injury: Drowning, Diving, Altitude, Heat, Cold, Electrical & Radiation 24.3 Obstetric & Genitourinary Emergencies and the Physiology of Pregnancy

25 Chapter 25: Transplantation, Donor Management & Post-Cardiac Surgery Care

25.1 Solid Organ Transplant Recipients & Deceased Donor Management 25.2 Post-Cardiac Surgery Critical Care: Bleeding, Tamponade, Low Output & Vasoplegia

26 Chapter 26: Hematologic Emergencies, Toxicology, Critical Ultrasound & ICU Liberation

26.1 Hematologic Emergencies in the ICU: HIT, DIC, TMA & Anticoagulant Reversal 26.2 Critical Care Toxicology, Toxidromes & Specific Antidotes 26.3 Critical Care Point-of-Care Ultrasound (POCUS) 26.4 ICU Liberation, Analgosedation, Goals of Care & Critical Care Ethics

27 Chapter 27: Transfusion Medicine, Hematologic & Oncologic Disorders

27.1 Transfusion Medicine: Products, Thresholds, Reactions & Apheresis 27.2 Red and White Cell Disorders, Hemoglobinopathies, Factor Deficiencies & Hypercoagulable States 27.3 Oncologic Emergencies, Hematopoietic Cell Transplant Complications & Cellular Therapy Toxicity

28 Chapter 28: Clinical Pharmacology, Adverse Drug Reactions & Specific Poisonings

28.1 Pharmacokinetic Principles, Dose Adjustment & Drug Interactions in Critical Illness 28.2 Adverse Drug Reactions: Anaphylaxis, Severe Cutaneous Reactions & Hyperthermic Syndromes 28.3 Specific Poisonings: Sodium-Channel Blockers, Lithium, Valproate, Theophylline, Iron, Sulfonylureas & Methemoglobinemia

29 Chapter 29: Ethics, Research Methods, Administration & Abdominal Ultrasound

29.1 Advance Care Planning, Nonbeneficial Treatment, Informed Consent & Confidentiality 29.2 Critical Care Research Methods, Statistics, IRB Oversight & Quality Improvement 29.3 Abdominal, Vascular & Procedural Point-of-Care Ultrasound

2.3 Refractory ARDS: Prone Positioning, Neuromuscular Blockade & VV-ECMO

Key Takeaways Explain This Topic AI

Prone positioning reduced mortality in severe ARDS (PaO2/FiO2 < 150 mmHg on FiO2 >= 0.60 and PEEP >= 5 cmH2O) in the PROSEVA trial (28-day mortality 16.0% vs. 32.8%; 90-day 23.6% vs. 41.0%) using sessions of at least 16 consecutive hours.

Early 48-hour cisatracurium improved adjusted 90-day survival in ACURASYS (crude mortality difference not significant), but the ROSE trial demonstrated that under contemporary lung-protective ventilation with light sedation, routine upfront paralysis does not improve mortality; NMBA should be reserved for refractory patient-ventilator dyssynchrony, breath-stacking, or severe hypoxemia.

Inhaled pulmonary vasodilators (inhaled nitric oxide and inhaled epoprostenol) improve PaO2/FiO2 by redistributing pulmonary blood flow to ventilated lung units, but do NOT reduce mortality or ventilator duration; their use is strictly restricted to temporary rescue bridging.

Venovenous extracorporeal membrane oxygenation (VV-ECMO) provides life support and halts VILI in severe ARDS meeting validated EOLIA trial criteria, with a post hoc Bayesian reanalysis estimating a high probability (88% to 99% depending on the prior) that early ECMO lowers 60-day mortality.

Last updated: October 2026

Tiered Escalation in Refractory ARDS

Refractory ARDS is defined clinically by persistent, severe hypoxemia ( PaO 2 / FiO 2 < 150 mmHg \text{PaO}_2/\text{FiO}_2 < 150\text{ mmHg} PaO 2 ​ / FiO 2 ​ < 150 mmHg , and particularly < 100 mmHg < 100\text{ mmHg} < 100 mmHg ) or unmanageable hypercapnic respiratory acidosis ( pH < 7.15 \text{pH} < 7.15 pH < 7.15 ) despite the optimization of lung-protective mechanical ventilation ( V T 6 mL/kg V_T\ 6\text{ mL/kg} V T ​ 6 mL/kg PBW, P plat ≤ 30 cmH 2 O P_{\text{plat}} \le 30\text{ cmH}_2\text{O} P plat ​ ≤ 30 cmH 2 ​ O , driving pressure < 14 cmH 2 O < 14\text{ cmH}_2\text{O} < 14 cmH 2 ​ O , and titrated high PEEP). Management requires a rapid, structured, and tiered escalation of evidence-based interventions: [Step 1: Baseline Lung-Protective Ventilation]

• Volume Assist-Control 6 mL/kg PBW (titrate down to 4 mL/kg if Pplat > 30 cmH2O)
• Titrate PEEP (Higher PEEP / Lower FiO2 strategy) | Target Delta P < 14 cmH2O
• Conservative Fluid Management (FACTT protocol: CVP < 4 mmHg or PAWP < 8 mmHg)
• │
• ▼ (If PaO2/FiO2 < 150 on FiO2 >= 0.60, PEEP >= 5)
• [Step 2: Early Prone Positioning + Targeted Neuromuscular Blockade]
• Prone positioning >= 16 consecutive hours/day (PROSEVA protocol)

- Deep sedation; if refractory patient-ventilator dyssynchrony or elevated Delta P persists:

• Initiate 48-hour continuous Cisatracurium infusion (ACURASYS)
• │
• ▼ (If PaO2/FiO2 remains < 100 or severe RV failure ensues)
• [Step 3: Rescue Physiological Adjuncts]
• Inhaled Pulmonary Vasodilators (Inhaled Epoprostenol 10-50 ng/kg/min or iNO 5-20 ppm)
• Optimize RV afterload; treat acute cor pulmonale
• │
• ▼ (EOLIA criteria: P/F < 50 for > 3 h, P/F < 80 for > 6 h, or pH < 7.25 + PaCO2 >= 60 for > 6 h)
• [Step 4: Venovenous Extracorporeal Membrane Oxygenation (VV-ECMO)]
• Emergent cannulation at or transfer to high-volume ECMO center
• Ultra-protective lung rest (Vt 2-4 mL/kg PBW, PEEP 10-15 cmH2O, RR 4-10/min, Delta P < 10)
• Prone Positioning and the PROSEVA Trial

Prone positioning is one of the only interventions in critical care medicine with a proven, robust mortality reduction in severe ARDS.

Physiological Mechanisms of Prone Positioning

Homogenization of Transpulmonary Pressure : In the supine position, gravitational hydrostatic pressure, cardiac mass, and cephalad displacement of the diaphragm by abdominal contents compress dependent dorsal lung regions, generating highly negative regional transpulmonary pressures and causing extensive dorsal atelectasis. In the prone position, the heart rests on the anterior sternum, and the dorsal lung is relieved of compressive forces. Transpulmonary pressure ( P tp = P alv − P pl P_{\text{tp}} = P_{\text{alv}} - P_{\text{pl}} P tp ​ = P alv ​ − P pl ​ ) becomes remarkably uniform from ventral to dorsal surfaces.

Preservation of Perfusion and Shunt Reduction : Pulmonary blood flow is governed by intrinsic vascular branching architecture and remains preferentially directed to dorsal lung regions, regardless of body position. When the patient is placed prone, the dorsal lung units re-expand while dorsal blood flow remains high, dramatically restoring ventilation-perfusion ( V / Q V/Q V / Q ) matching and eliminating right-to-left intrapulmonary shunt.

Reduction in Cyclic Strain and VILI : Homogeneous distribution of tidal volume prevents excessive regional hyperinflation of ventral units and cyclic opening/closing of dorsal units, directly reducing atelectrauma and biotrauma.

Enhanced Secretion Clearance : Dependent drainage of secretions from the tracheobronchial tree is facilitated.

The PROSEVA Landmark Trial (Guérin et al., NEJM 2013)

The PROSEVA trial randomized 466 patients with severe, confirmed ARDS ( PaO 2 / FiO 2 < 150 mmHg \text{PaO}_2/\text{FiO}_2 < 150\text{ mmHg} PaO 2 ​ / FiO 2 ​ < 150 mmHg on FiO 2 ≥ 0.60 \text{FiO}_2 \ge 0.60 FiO 2 ​ ≥ 0.60 , PEEP ≥ 5 cmH 2 O \text{PEEP} \ge 5\text{ cmH}_2\text{O} PEEP ≥ 5 cmH 2 ​ O , and V T V_T V T ​ about 6 mL/kg 6\text{ mL/kg} 6 mL/kg PBW, confirmed after a 12-to-24-hour stabilization period) to either prone positioning or supine positioning. Prone sessions were mandated for at least 16 consecutive hours per day .

The findings demonstrated an exceptional mortality reduction:

28-Day Mortality : 16.0% in the prone group vs. 32.8% in the supine group ( p < 0.001 p < 0.001 p < 0.001 , hazard ratio 0.39, 95% CI 0.25-0.63).

90-Day Mortality : 23.6% in the prone group vs. 41.0% in the supine group ( p < 0.001 p < 0.001 p < 0.001 ).

Number Needed to Treat (NNT) : Approximately 6 patients to save one life.

Discontinuation Criteria : Prone therapy was stopped when PaO 2 / FiO 2 ≥ 150 mmHg \text{PaO}_2/\text{FiO}_2 \ge 150\text{ mmHg} PaO 2 ​ / FiO 2 ​ ≥ 150 mmHg was sustained with PEEP ≤ 10 cmH 2 O \text{PEEP} \le 10\text{ cmH}_2\text{O} PEEP ≤ 10 cmH 2 ​ O and FiO 2 ≤ 0.60 \text{FiO}_2 \le 0.60 FiO 2 ​ ≤ 0.60 for at least 4 hours after returning to the supine position.

Important

Prone positioning must be maintained for ≥ 16 \ge 16 ≥ 16 consecutive hours per session to achieve the mortality benefits established in PROSEVA. Brief proning trials (e.g., 4 to 6 hours) do not improve mortality and increase the risk of procedural line and airway complications.

Contraindications and Complications

Absolute Contraindications : Unstable spinal fractures, severe open facial or pelvic trauma, open abdomen with active packing, refractory ventricular arrhythmias, and acute massive hemoptysis.

Relative Contraindications : Acute elevated intracranial pressure (ICP), pregnancy, severe hemodynamic instability requiring high-dose vasopressors, recent sternotomy, and deep venous thrombosis treated < 48 hours < 48\text{ hours} < 48 hours .

Complications : Endotracheal tube extubation or kinking, central venous and arterial line dislodgement, facial, thoracic, and knee pressure ulcers, brachial plexus neuropraxia, and transient facial/airway edema.

Neuromuscular Blockade: ACURASYS vs. ROSE Trials

Neuromuscular blockade eliminates active patient breathing efforts that generate high transpulmonary pressures, eliminates patient-ventilator dyssynchrony (e.g., double-triggering, reverse triggering, breath-stacking), decreases patient-self-inflicted lung injury (P-SILI) and Pendelluft (intra-pulmonary gas redistribution between lung regions during uncoordinated diaphragmatic contraction), and decreases total body metabolic oxygen consumption and CO 2 \text{CO}_2 CO 2 ​ production.

ACURASYS (Papazian et al., NEJM 2010)

The French ACURASYS trial evaluated 340 patients with early, severe ARDS ( PaO 2 / FiO 2 < 150 mmHg \text{PaO}_2/\text{FiO}_2 < 150\text{ mmHg} PaO 2 ​ / FiO 2 ​ < 150 mmHg within 48 hours of onset). Patients received a continuous infusion of cisatracurium besylate for 48 hours versus placebo. Both groups received deep sedation. Crude 90-day mortality was 31.6% vs. 40.7% ( p = 0.08 p = 0.08 p = 0.08 ); after adjustment for baseline PaO2/FiO2, plateau pressure, and SAPS II, the hazard ratio for death was 0.68 (95% CI 0.48-0.98, p = 0.04 p = 0.04 p = 0.04 ). Cisatracurium also increased ventilator-free days and reduced barotrauma without increasing ICU-acquired weakness.

PETAL ROSE Trial (Moss et al., NEJM 2019)

The multicenter PETAL ROSE trial evaluated 1,006 patients with moderate-to-severe ARDS ( PaO 2 / FiO 2 < 150 mmHg \text{PaO}_2/\text{FiO}_2 < 150\text{ mmHg} PaO 2 ​ / FiO 2 ​ < 150 mmHg on PEEP ≥ 8 cmH 2 O \text{PEEP} \ge 8\text{ cmH}_2\text{O} PEEP ≥ 8 cmH 2 ​ O ) comparing early continuous cisatracurium infusion with deep sedation against a contemporary control strategy of light sedation targets (RASS -1 to 0) without routine neuromuscular blockade.

ROSE revealed no difference in 90-day in-hospital mortality (42.5% in the neuromuscular blockade group vs. 42.8% in the control group, p = 0.93 p = 0.93 p = 0.93 ). Furthermore, patients in the neuromuscular blockade group experienced significantly more serious cardiovascular adverse events (including bradycardia and hypotension) and delayed physical mobilization.

Evidence Synthesis for the Boards

Routine continuous neuromuscular blockade for every patient with PaO 2 / FiO 2 < 150 mmHg \text{PaO}_2/\text{FiO}_2 < 150\text{ mmHg} PaO 2 ​ / FiO 2 ​ < 150 mmHg is not supported by ROSE. The 2024 ATS guideline makes a conditional recommendation for neuromuscular blockade in early severe ARDS, and the Surviving Sepsis Campaign (2021, reaffirmed 2026) suggests intermittent boluses over a continuous infusion. A practical synthesis:

Initial management targeting light-to-moderate analgosedation with lung-protective ventilation.

Reserving continuous neuromuscular blockade (for up to 48 hours) strictly for patients who exhibit refractory patient-ventilator dyssynchrony , severe breath-stacking generating high driving pressures, persistent shivering, or severe refractory hypoxemia despite deep sedation and prone positioning.

Inhaled Pulmonary Vasodilators

Inhaled vasodilators include inhaled nitric oxide (iNO, 5 to 20 ppm) and inhaled epoprostenol / prostacyclin ( PGI 2 \text{PGI}_2 PGI 2 ​ , 10 to 50 ng/kg/min) .

Mechanism of Action

Unlike intravenously administered vasodilators, which indiscriminately dilate both ventilated and non-ventilated pulmonary vascular beds (worsening shunt and systemic hypotension), inhaled vasodilators are delivered selectively to well-ventilated alveolar units . They induce local cyclic GMP (iNO) or cyclic AMP (epoprostenol) mediated relaxation of adjacent vascular smooth muscle, redistributing pulmonary arterial blood flow away from non-ventilated consolidated units to aerated units. This significantly improves V / Q V/Q V / Q matching, reduces intrapulmonary shunt, and reduces right ventricular afterload.

Clinical Efficacy & Trial Outcomes

Multiple randomized clinical trials and systematic Cochrane reviews demonstrate that while inhaled pulmonary vasodilators produce a rapid, statistically significant improvement in arterial oxygenation (increasing PaO 2 / FiO 2 \text{PaO}_2/\text{FiO}_2 PaO 2 ​ / FiO 2 ​ by 20% to 30%), they confer no improvement in mortality, ventilator-free days, or ICU duration . Consequently, guidelines recommend against routine use; they are reserved strictly as a temporary rescue bridge to maintain oxygenation while mobilizing for prone positioning, VV-ECMO cannulation, or the resolution of acute right heart failure.

Toxicities and Monitoring

Inhaled Nitric Oxide (iNO) :

Binds avidly to hemoglobin to form methemoglobin . Daily methemoglobin levels must be monitored; levels > 3 % > 3\% > 3% mandate dose reduction, and levels > 5 % > 5\% > 5% require cessation and potentially methylene blue therapy ( 1 – 2 mg/kg 1\text{--}2\text{ mg/kg} 1 – 2 mg/kg IV).

Combines with ambient oxygen to form nitrogen dioxide ( NO 2 \text{NO}_2 NO 2 ​ ), an airway irritant and toxin (keep NO 2 < 2 ppm \text{NO}_2 < 2\text{ ppm} NO 2 ​ < 2 ppm ).

Causes dose-dependent renal tubular injury and increased risk of acute kidney injury.

Inhaled Epoprostenol :

Glycine buffer and aerosolized drug can crystalize within the ventilator circuit, clogging expiratory filters. This risks acute expiratory valve obstruction, life-threatening dynamic hyperinflation, and tension barotrauma; expiratory filters must be changed every 2 to 4 hours.

Rebound Hypoxemia : Abrupt cessation of either agent precipitates acute rebound pulmonary arterial vasoconstriction and catastrophic arterial hypoxemia. They must always be weaned gradually in step decrements.

Venovenous Extracorporeal Membrane Oxygenation (VV-ECMO)

Venovenous ECMO provides complete extracorporeal gas exchange (oxygenation and carbon dioxide removal), bypassing the pulmonary circulation without providing direct hemodynamic circulatory support.

Circuit Mechanics

Deoxygenated venous blood is extracted from the inferior vena cava via a large drainage cannula (21 to 25 Fr) placed through the femoral vein, driven through an extracorporeal centrifugal pump into a polymethylpentene hollow-fiber membrane lung, and returned oxygenated and decarboxylated into the right atrium via a reinfusion cannula (17 to 21 Fr) positioned in the right internal jugular vein (or via a single bicaval dual-lumen cannula).

Oxygenation ( Q b Q_b Q b ​ ) : Governed primarily by extracorporeal blood flow rate ( L / min ⁡ L/\min L / min ). To maintain adequate systemic oxygenation (target arterial saturation ≥ 88 % \ge 88\% ≥ 88% ), ECMO blood flow must typically supply at least 60% to 70% of the patient's cardiac output (usually 4 to 6 L/min).

CO 2 \text{CO}_2 CO 2 ​ Removal (Sweep Gas Flow) : Governed by the sweep gas flow rate ( L / min ⁡ L/\min L / min ). Increasing sweep gas rapidly clears dissolved CO 2 \text{CO}_2 CO 2 ​ across the membrane lung, allowing immediate normalization of severe respiratory acidosis.

"Ultra-Lung-Protective Rest" Ventilation : Once VV-ECMO is established, mechanical ventilator settings are reduced to resting parameters: V T 2 – 4 mL/kg V_T\ 2\text{--}4\text{ mL/kg} V T ​ 2 – 4 mL/kg PBW, respiratory rate 4 to 10 breaths/min, PEEP 10 – 15 cmH 2 O 10\text{--}15\text{ cmH}_2\text{O} 10 – 15 cmH 2 ​ O , and plateau pressure ≤ 25 cmH 2 O \le 25\text{ cmH}_2\text{O} ≤ 25 cmH 2 ​ O (driving pressure < 10 cmH 2 O < 10\text{ cmH}_2\text{O} < 10 cmH 2 ​ O ), completely resting the lung to promote parenchymal healing.

The EOLIA Trial (Combes et al., NEJM 2018)

The landmark EOLIA trial established the validated clinical criteria for initiating VV-ECMO in severe ARDS:

PaO 2 / FiO 2 < 50 mmHg \text{PaO}_2/\text{FiO}_2 < 50\text{ mmHg} PaO 2 ​ / FiO 2 ​ < 50 mmHg for > 3 hours > 3\text{ hours} > 3 hours despite FiO 2 ≥ 0.80 \text{FiO}_2 \ge 0.80 FiO 2 ​ ≥ 0.80 and PEEP ≥ 10 cmH 2 O \text{PEEP} \ge 10\text{ cmH}_2\text{O} PEEP ≥ 10 cmH 2 ​ O ; OR

PaO 2 / FiO 2 < 80 mmHg \text{PaO}_2/\text{FiO}_2 < 80\text{ mmHg} PaO 2 ​ / FiO 2 ​ < 80 mmHg for > 6 hours > 6\text{ hours} > 6 hours despite FiO 2 ≥ 0.80 \text{FiO}_2 \ge 0.80 FiO 2 ​ ≥ 0.80 and PEEP ≥ 10 cmH 2 O \text{PEEP} \ge 10\text{ cmH}_2\text{O} PEEP ≥ 10 cmH 2 ​ O ; OR

Arterial pH < 7.25 \text{pH} < 7.25 pH < 7.25 for > 6 hours > 6\text{ hours} > 6 hours resulting from severe hypercapnia ( PaCO 2 ≥ 60 mmHg \text{PaCO}_2 \ge 60\text{ mmHg} PaCO 2 ​ ≥ 60 mmHg ) with respiratory rate set to 35 breaths/min and P plat ≤ 32 cmH 2 O P_{\text{plat}} \le 32\text{ cmH}_2\text{O} P plat ​ ≤ 32 cmH 2 ​ O .

Outcome Parameter ECMO Group ( n = 124 n = 124 n = 124 ) Conventional Group ( n = 125 n = 125 n = 125 ) Relative Risk / p p p -value

• 60-Day Mortality 35% 46% RR 0.76 \text{RR } 0.76 RR 0.76 ( p = 0.09 p = 0.09 p = 0.09 , primary endpoint)
• Treatment Crossover N/A 35 patients (28%) crossed over to rescue ECMO 43% of rescue crossovers survived

Treatment Failure (Death or Crossover) 35% 58% RR 0.62 \text{RR } 0.62 RR 0.62 ( p < 0.001 p < 0.001 p < 0.001 )

Bayesian Re-analysis (Goligher et al., JAMA 2018) 96% posterior probability of any mortality benefit with a minimally informative prior (88% to 99% across priors); probability of a large benefit (RR < 0.67) about 18%

Note

Although the intention-to-treat 60-day mortality difference in EOLIA narrowly missed conventional statistical significance ( p = 0.09 p = 0.09 p = 0.09 ), 28% of the conventional management cohort experienced catastrophic refractory hypoxemic arrest and crossed over to emergency rescue ECMO, diluting the observed mortality difference. Treatment failure (death or crossover) was clearly lower with ECMO, and Bayesian reanalysis suggests a probable mortality benefit, which is why guidelines support VV-ECMO for selected patients at experienced centers (ATS 2024 conditional recommendation).

Anticoagulation and Complications

Anticoagulation : Requires systemic unfractionated heparin infusion targeting an anti-factor Xa level of 0.3 – 0.5 IU/mL 0.3\text{--}0.5\text{ IU/mL} 0.3 – 0.5 IU/mL (or aPTT 50 to 70 seconds) to prevent circuit and membrane thrombosis.

Hemorrhagic Complications : The leading cause of ECMO-related morbidity; intracranial hemorrhage occurs in 5% to 7% and is frequently fatal.

Recirculation : Occurs when oxygenated blood returning from the reinfusion cannula is immediately drawn back into the drainage cannula without entering the systemic circulation. Manifests as high pre-membrane saturation ( S pre O 2 > 80 % S_{\text{pre}}\text{O}_2 > 80\% S pre ​ O 2 ​ > 80% ) combined with persistent patient arterial hypoxemia. Managed by physically increasing the distance between cannula tips or repositioning under fluoroscopic/echocardiographic guidance.